Related Experiment Video

Updated: May 23, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.1K

The role of RAC1 in resistance to targeted therapies in cancer

Cristina Uribe-Alvarez1, Jonathan Chernoff1

  • 1Cancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.

Small Gtpases
|May 21, 2025
PubMed

Insights

The Rho GTPase RAC1 (Ras-related C3 botulinum toxin substrate 1) is crucial for cell growth and actin dynamics. Aberrant RAC1 activity drives cancer progression and drug resistance, necessitating new therapeutic strategies.

Area of Science:

  • Molecular biology
  • Cell biology
  • Oncology

Background:

  • RAC1 (Ras-related C3 botulinum toxin substrate 1) is a key regulator of actin cytoskeleton dynamics and cell growth.
  • Dysregulated RAC1 activity, through mutations or overexpression, contributes to oncogenesis and is implicated in various cancers.
  • Combined RAC1 mutations with other oncogenic drivers (e.g., BRAF, NRAS) exacerbate drug resistance and worsen patient prognosis.

Purpose of the Study:

  • To review the role of RAC1 in cancer development and drug resistance.
  • To highlight the challenges and current strategies in targeting RAC1 therapeutically.
  • To explore potential future directions for RAC1-targeted therapies.

Main Methods:

  • Literature review of RAC1's role in cancer.
  • Analysis of RAC1's involvement in oncogenic phenotypes and drug resistance.
  • Summary of current and emerging therapeutic approaches targeting RAC1.

Main Results:

  • Increased RAC1 activity promotes cancer hallmarks like proliferation and metastasis.
  • RAC1 mutations, especially combined with other drivers, are linked to poor prognosis and treatment failure.
  • Targeting RAC1's activity, localization, activators, or expression presents potential therapeutic avenues.

Conclusions:

  • RAC1 is a significant factor in cancer progression and drug resistance.
  • Targeting RAC1 is challenging due to its essential cellular functions but offers promising therapeutic potential.
  • Future research should focus on novel strategies to effectively inhibit RAC1 in cancer treatment.
Keywords:
RAC1RHO GTPasesSignal transductioncancerdrug resistance

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.2K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K